Enanta Pharmac announces topline results showing EDP-938 achieved its endpoints
Enanta Pharmaceuticals announced topline results demonstrated that EDP-938 achieved highly statistically significant reductions in viral load and in resolution of clinical symptoms compared to placebo in its Phase 2a human challenge study of EDP-938 in healthy adults infected with RSV. June 14, 2019